Clinical Trial Update: A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS) [Phase 1]

View source ↗

Summary

The Phase 1 OASIS study evaluating onCARlytics CF33-CD19 CAR-T in combination with blinatumomab in adults with advanced or metastatic solid tumors has been term…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Blinatumomab (blinatumomab)
• onCARlytics CF33-CD19 (CF33-CD19 CAR-T)

Snippet

Sponsor: Imugene Limited | Conditions: Solid Tumor, Adult | Phase 1 | Status: TERMINATED